Bangladess - enska - DGDA (Directorate General of Drug Administration)

aristopharma limited - azithromycin - tablet - 500 mg

Bangladess - enska - DGDA (Directorate General of Drug Administration)

aristopharma limited - azithromycin - eye drops - 1 gm/100 ml

Panama - enska - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorio sophia s.a. de c.v. - clorhidrato de azelastina - clorhidrato de azelastina....0.50 mg.

Singapúr - enska - HSA (Health Sciences Authority)

kang sheng chinese medicine manufacturer pte. ltd. - pills

Úganda - enska - National Drug Authority

gittoes pharmaceuticals limited; gittoes pharmaceuticals limited - azithromycin - oral solid ordinary tablets - 500mg

Úganda - enska - National Drug Authority

gittoes pharmaceuticals limited; gittoes pharmaceuticals limited - azithromycin - oral solid ordinary tablets - 250mg

Úganda - enska - National Drug Authority

kopran limited - azithromycin dihydrate - oral solid ordinary film-coated tablets - 500 mg

Kenía - enska - Pharmacy and Poisons Board

zain pharma limited plot no. 209/13741, colchester park, go-down - albendazole - oral suspension - 200mg/5ml - albendazole

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - osimertinib mesilate, quantity: 47.7 mg (equivalent: osimertinib, qty 40 mg) - tablet, film coated - excipient ingredients: purified talc; polyvinyl alcohol; hyprolose; iron oxide black; mannitol; titanium dioxide; macrogol 3350; sodium stearylfumarate; iron oxide red; iron oxide yellow; microcrystalline cellulose; purified water - tagrisso is indicated:,? as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have activating epidermal growth factor receptor (egfr) mutations, as detected by a validated test.,? for the first-line treatment of patients with locally advanced or metastatic nsclc whose tumours have activating egfr mutations, as detected by a validated test.,? for the treatment of patients with locally advanced or metastatic nsclc that is egfr t790m mutation-positive, as detected by a validated test.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - osimertinib mesilate, quantity: 95.4 mg (equivalent: osimertinib, qty 80 mg) - tablet, film coated - excipient ingredients: iron oxide black; sodium stearylfumarate; polyvinyl alcohol; purified talc; titanium dioxide; iron oxide red; macrogol 3350; mannitol; hyprolose; iron oxide yellow; microcrystalline cellulose - tagrisso is indicated:,? as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (nsclc) whose tumours have activating epidermal growth factor receptor (egfr) mutations, as detected by a validated test.,? for the first-line treatment of patients with locally advanced or metastatic nsclc whose tumours have activating egfr mutations, as detected by a validated test.,? for the treatment of patients with locally advanced or metastatic nsclc that is egfr t790m mutation-positive, as detected by a validated test.